AGTR1 and preeclampsia: Our group has recently demonstrated that exaggerated ang II-mediated constriction can be reduced in the microvasculature with local or systemic pharmacological inhibition of AT1R [13,14], or local activation of the counterregulatory RAAS with ang 1–7 [12] or AT2R agonism [15], suggesting that approaches that counteract excessive AT1R activation may be feasible strategies to improve vascular function in women who had preeclampsia prior to the onset of chronic CVD.